ClinicalTrials.gg
CompletedNCT04500132Updated Feb 10, 2022

To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia

A Phase 2 interventional study of EC-18 and Placebo EC-18 in COVID-19, sponsored by Enzychem Lifesciences Corporation. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2022-02-10.

Sponsored by Enzychem Lifesciences Corporation · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 90 studies in COVID-19 with a site in Korea, Republic of — 11 open to participants now, 19 under way, 6 of them phase 3. COVID-19 · Korea, Republic of.

Enrollment
50th of 72
63 · median 253
Started
2020
with 28 others
Phase 2
17 of 90
2 open now
Registered
16th of 90
by date

Among the 90 studies in COVID-19 with a site in Korea, Republic of, this one is the 50th largest by enrollment of the 72 interventional ones that give a count, is one of 29 that started in 2020, is one of 17 in phase 2, and was the 16th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

11 of the 90 studies in COVID-19 with a site in Korea, Republic of are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in COVID-19 with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Prevention of COVID-19 infection to severe pneumonea or ARDS

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Male or female age 19 years or older
  • confirmed diagnosis of COVID-19 Infection to Pneumonia

Exclusion criteria

Exclusion Criteria:

  • confirmed diagnosis of bacterial pneumonia or viral pneumonia
  • Pregnant or nursing at the time of signing
  • Known sensitivity to any study medication
  • Unwilling or unable to complete study diary
  • Any other condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the protocol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    EC-18 Arm

    EC-18 QD

    Drug: EC-18

  • Placebo comparator
    Placebo Arm

    Placebo EC-18 QD

    Drug: Placebo EC-18

Interventions

06

What researchers measure

Primary outcomes

  1. Rate of transition to ARDS

    Time frame: 14 days after starting IP administration

07

Study locations

1 site
  • Chungbuk National University Hospital
    Cheongju-si, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Feb 2021, 8 months.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 8 months is close to that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2020
First posted
Aug 5, 2020
StartActual
May 28, 2020
Primary completionActual
Feb 4, 2021
CompletionActual
Feb 15, 2021
Last update
Feb 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04500132
Lead sponsor
Enzychem Lifesciences Corporation
Responsible party
Sponsor
First posted
Aug 5, 2020
Start date
May 28, 2020
Primary completion
Feb 4, 2021
Completion
Feb 15, 2021
Last update
Feb 10, 2022

Study contacts

Hyewon Jeong
principal investigator · Chungbuk National University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mosedipimod

Start the discussion